Bruce Cree, AAN 2022: Ublituximab and its potential use in the treatment of relapsing multiple sclerosis

Ublituximab is a novel glycoengineered monoclonal antibody treatment under investigation for relapsing remitting multiple sclerosis. Prof. Bruce Cree (UCSF Multiple Sclerosis Centre, San Francisco, CA, USA) discusses ublituximab’s novel mode of action, and the potential advantages of ublituximab compared with other antibodies targeting CD20-expressing B-cells in the relapsing multiple sclerosis (RMS).

The abstract entitled ‘Disability Improvements With Ublituximab in Relapsing Multiple Sclerosis (RMS): Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9-HPT), and Timed 25-Foot Walk (T25FW) Evaluations From the Phase 3 ULTIMATE I and II Studies’ was presented at the American Academy of Neurology (AAN) annual meeting, April 2-7, 2022.

View more content from Prof. Bruce Cree:

Bruce Cree, AAN 2022: Bruton tyrosine kinase inhibitors in multiple sclerosis – Key clinical highlights

Bruce Cree, AAN 2022: Disability improvements with ublituximab in relapsing multiple sclerosis – Phase 3 ULTIMATE I and II

Questions:

1. Could you tell us a little about ublituximab and its mechanism of action? (0:15)
2. What are the potential advantages of ublituximab compared with other antibodies targeting CD20-expressing B-cells? (0:43)

Disclosures: Bruce Cree is a consultant for Alexion, Atara, Autobahn, Avotres, Biogen, EMD Serono, Gossamer Bio, Horizon, Neuron23, Novartis, Sanofi, TG Therapeutics and Therini; and receives grant/research support from Genentech; and is also on the advisory board for Autobahn.

Support:  Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of AAN 2022